The move holds importance because the low-cost drugs were on the verge of vanishing from the Indian market — similar to multiple other formulations for which Indian makers are now dependent on imports from China
Asthma, Glaucoma, Thalassemia, TB & More: Regulator Approves 50% Hike for 8 Low-Cost Drugs